A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Osimertinib
Related studies linked through entity extraction aliases.
Osimertinib Combined With Intracranial SRT for EGFR-Mutant NSCLC With Symptomatic Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
A Phase Ⅲ Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients
- Status
- RECRUITING
- Phase
- N/A
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
- Status
- RECRUITING
- Phase
- PHASE2
A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
- Status
- RECRUITING
- Phase
- PHASE3
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations
- Status
- RECRUITING
- Phase
- PHASE3
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
- Status
- NOT_YET_RECRUITING
- Phase
- NA